NCT05242991 is a NA clinical trial of Photobiomodulation therapy in Mucositis, sponsored by Federal University of Rio Grande do Sul.

Who is sponsoring NCT05242991?

NCT05242991 is sponsored by Federal University of Rio Grande do Sul.

What drugs are being tested in NCT05242991?

Interventions in NCT05242991: Photobiomodulation therapy.

What condition does NCT05242991 study?

NCT05242991 studies Mucositis, Xerostomia, Hyposalivation.

Is NCT05242991 still recruiting?

NCT05242991 is currently status unknown. Last updated 9 March 2023.

Last reviewed 2023-03-09 · How we verify

NCT05242991

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer Patients

Status unknown NA Last updated 9 March 2023

What this trial tests

NA trial testing Photobiomodulation therapy in Mucositis in 132 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 March 2023

1 October 2024

Quick facts

Lead sponsor	Federal University of Rio Grande do Sul
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	132
Start date	1 March 2021
Primary completion	1 March 2023
Estimated completion	1 October 2024
Sites	1 location across Brazil

Drugs / interventions tested

Photobiomodulation therapy

Conditions studied

Mucositis — all drugs for Mucositis →
Xerostomia — all drugs for Xerostomia →
Hyposalivation — all drugs for Hyposalivation →

Sponsor

Federal University of Rio Grande do Sul

Who can join

Adults 18 to 90, any sex, with Mucositis or Xerostomia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Head and neck cancer (HNC) are among the most frequent malignancies in the world. The main treatment modalities for HNC are surgical excision, radiotherapy (RT), and chemotherapy (CT). Severe oral sequelae such as oral mucositis (OM), dysgeusia, opportunistic infections, trismus, and xerostomia/hyposalivation can affect HNC patients due to oncological treatment with RT and QT. Photobiomodulation therapy (PBMT) with an intraoral low-power laser has been studied as an excellent tool in the management of OM and xerostomia and thus improves the tolerability of RT in the head and neck region. The aim of this multicenter, randomized, single-blind clinical trial is to compare the effects of two photobiomodulation protocols (intraoral application low-level laser and defocused extraoral application of high-power laser) in the management of oral mucositis (OM) and xerostomia in head and neck cancer patients undergoing radiotherapy (RT). It is expected defocused extraoral high-power photobiomodulation shows results as good as intraoral photobiomodulation on the management of oral mucositis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer treatment-related xerostomia: basics, therapeutics, and future perspectives.
Hosseini MS, Sanaie S, Mahmoodpoor A, Jabbari Beyrami S, et al · · 2024 · cited 12× · PMID 39614391 · DOI 10.1186/s40001-024-02167-x
Intraoral vs. extraoral photobiomodulation therapy for oral mucositis in head and neck cancer patients: a multicenter, randomized, single-blind clinical trial.
Klein IP, Pinto MBR, Só BB, de Farias Gabriel A, et al · · 2025 · PMID 40928526 · DOI 10.1007/s00520-025-09877-w

Verify or expand the search:

Other trials of Photobiomodulation therapy

Trials testing the same drug.

NCT06145867 — A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis · NA · enrolling by invitation
NCT05595564 — Influence of PBM on Anaerobic Capacity Under Normoxia and Hypoxia · NA · unknown
NCT04036994 — PBMT for the Management of CIA ( HAIRLASER ) · NA · unknown

Other recruiting trials for Mucositis

Currently open trials in the same condition.

NCT06599346 — Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients · NA · recruiting
NCT03581773 — Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients R · Phase 2 · recruiting

Other Federal University of Rio Grande do Sul trials

Trials by the same sponsor.

NCT06967493 — Effects of Amazonian Dance on Motor and Non-motor Symptoms of People With Parkinson's: Study Protocol · NA · recruiting
NCT07470450 — Acute and Chronic Effects of Combined Training on BP in Hypertensives · NA · completed
NCT07023146 — Effects of Different Power Training Intensities in Older Adults · NA · enrolling by invitation
NCT06912269 — Effects of Strength Training on the Plantar Flexors' Properties After Achilles Tendon Rupture · NA · recruiting
NCT06416046 — Efficacy of Photobiomodulation in the Treatment and Relief of Pain in Recurrent Aphthous Stomatitis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05242991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federal University of Rio Grande do Sul
Last refreshed: 9 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05242991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing